Title: Long-term risk of cancer following pregnancies complicated by vaginal bleeding

Elena Dudukina,[1] Erzsébet Horváth-Puhó,[1] Henrik Toft Sørensen,[1] Vera Ehrenstein[1]

[1]Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Corresponding author:

Elena Dudukina

Olof Palmes Alle 43-45

8200

Aarhus N

Email: e.dudukina@clin.au.dk

Word count: 2679

Abstract word count: 272

ABSTRACT

Objective: To investigate an association of vaginal bleeding-affected deliveries with the long-term risk of cancer as compared with vaginal bleeding-unaffected deliveries and pregnancies ending in a termination or miscarriage.

Design: Registry-based cohort study in Denmark, 1995-2017.

Setting: Danish health and administrative registries.

Participants: Deliveries (N=37,085) affected by vaginal bleeding (VB) within 20 gestational weeks among 35,517 women, VB-unaffected deliveries (N=1,362,760) among 783,020 women, pregnancies ending in a termination (N=324,395) among 239,729 women or miscarriage (N=137,040) among 121,303 women.

Main outcome measures: Incidence rates (IR) per 10,000 person-years and cumulative incidence of cancer at the end of up to 24 years of follow-up, hazard ratios (HR) with 95% confidence intervals (CIs) adjusted for age, calendar year, reproductive history, history of chronic conditions, medication use, and socioeconomic factors using Cox proportional hazards regression.

Results: We observed 1,725 cancer events (IR=32.1, 95% CI: 30.6-33.6) following VB-affected deliveries, 52,620 events (IR=31.5, 95% CI: 31.2-31.7) following VB-unaffected deliveries, 12,925 events (IR=30.1, 95% CI: 29.6-30.6) following a termination and 6,080 events (IR=34.3, 95% CI: 33.4-35.1) following a miscarriage. We found no association between VB and any cancer in comparison with VB-unaffected deliveries (HR=0.98, 95% CI: 0.93-1.03), terminations (HR=1.00, 95% CI: 0.94-1.06) and miscarriages (HR=1.04, 95% CI: 0.94-1.14). Specifically, there was no increase in relative risk of breast (HR=0.94, 95% CI: 0.86-1.03), cervical (0.94, 0.77-1.14), ovarian and fallopian tube (1.16, 0.81-1.66), uterine cancer (0.78, 0.46-1.33) and other site-specific cancers across all comparisons and in sensitivity analyses.

Conclusions: Having a VB-affected pregnancy ending in a delivery was not associated with an increased women's risk of cancer in comparison with having a VB-unaffected pregnancy ending in a delivery, termination or miscarriage.

WHAT IS ALREADY KNOWN ON THIS TOPIC
• The risk of breast, endometrial, and ovarian cancer is reduced in women with childbirths. • The risk reduction for breast, endometrial, and ovarian cancer is also observed following pregnancies ending in a termination or miscarriage, suggesting a protective association with gestation irrespective of its outcome.
WHAT THIS STUDY ADDS
• When compared with vaginal bleeding-unaffected deliveries, affected deliveries were not associated with the increased risk of any cancer and specifically of breast, cervical, ovarian and fallopian tube, and uterine cancer during the follow-up of up to 24 years. • In comparison with pregnancies ending in a termination or miscarriage, pregnancies affected by vaginal bleeding were also not associated with subsequent risk of cancer.

INTRODUCTION

A full-term pregnancy is associated with a 40% reduction in risks of breast, endometrial, and ovarian cancer.[1,2] A pregnancy irrespective of outcome is associated with a reduction in risks of endometrial, breast, and ovarian cancers.[1,3,4] However, pregnancy ending in a miscarriage is associated with a less pronounced protective effect against cancer of 10%.[4]

Gestation is sustained with progesterone that may play a protective role for hormone-related cancers, such as endometrial and breast cancer.[3,4] Threatened and completed miscarriage share several biologic mechanisms, including increased levels of pro-inflammatory cytokines[5–7] and decreased levels of progesterone.[8,9] Threatened miscarriage affects up to 30%[10–14] of pregnancies and manifests as vaginal bleeding (VB), often during the first trimester.[10,11,15] About 30-50%[8,16,17] of VB-affected deliveries end in a miscarriage.[18–20]

The long-term risk of cancer in women with a pregnancy complicated by vaginal bleeding within 20 gestational weeks is unknown. A previous Danish study showed that VB in pregnancy is not a marker of occult cancer.[21] In this registry-based cohort study in Denmark, we investigated an association of VB-affected deliveries with the subsequent risk of cancer as compared with VB-unaffected deliveries and pregnancies ending in a termination or miscarriage.

METHODS

Setting, design and data sources

This was a registry-based cohort study conducted using patient-level linked data from Danish health and administrative registries,[22] set within Denmark's universal and tax-funded health care system. The Civil Registration System[22,23] assigns personal identifiers and contains data on date of birth, vital and civil status, dates of immigration and emigration. Data on all deliveries are captured by the Medical Birth Registries (MBR) starting in 1973[24,25] and includes women's and pregnancy-related characteristics (women's age at delivery, gestational age, parity). Smoking status in pregnancy is

collected by the MBR from 1991 and body-mass index (BMI) from 2004. Information on stillbirths at the gestational age of at least 28 full weeks is available in the MBR before April 2004 and at 22 full gestational weeks afterwards; livebirths are recorded regardless of gestational age. Information on highest education level,[26] employment status[27] and personal income[28] are stored at Statistics Denmark and available starting in 1980.[29] Hospital encounters are recorded in the Danish National Patient Registry (DNPR),[30,31] including data on medical procedures and discharge diagnoses, coded using the International Classification of Diseases, 8th revision (ICD-8) in 1977-1993 and 10th revision (ICD-10) thereafter.[30] Hospital admissions are available in the DNPR from 1977, while outpatient clinic and emergency room visits are recorded from 1995 onwards.[30,31] Admissions and outpatient specialist visits due to psychiatric conditions are captured by the Psychiatric Central Research Register[32] and were available in this study from 1995. The Danish National Prescription Registry[33] captures data on prescribed medication dispensings from 1995 onwards and records the Anatomical Therapeutic Classification (ATC) codes of the dispensed drugs and the dates when the prescriptions were redeemed. The Danish Cancer Registry (DCR)[34] captures all primary incident cancer diagnoses and contains data on tumours' morphology.

Pregnancies affected by vaginal bleeding within 20 weeks of gestation and ending in delivery

Using the MBR, we identified all deliveries between 1995 and 2017. We kept one record per delivery of a multifetal pregnancy. Using the DNPR, we obtained data on VB within 20 gestational weeks starting from the last menstrual period date, computed by subtracting gestational age at delivery from the delivery date (Table S1 in the Supplemental materials). When several VB episodes were recorded during the same gestation, we included the earliest. The index date for the affected pregnancies was the date of the hospital-based encounter due to a VB during the first 20 gestational weeks.

Pregnancies ending in delivery unaffected by vaginal bleeding and pregnancies ending in a termination or miscarriage

Pregnancies ending in delivery without a VB diagnosis in the DNPR during 20 weeks of gestation were classified as VB-unaffected. The index date for VB-unaffected deliveries was the date of delivery. Using the DNPR, we identified pregnancies ending in a miscarriage (spontaneous abortion) or a termination (medical or surgical abortion) in 1995-2017, using all recorded diagnoses. To identify pregnancy terminations, we also used procedure codes from the DNPR (Table S1 in the Supplemental materials). To limit the inclusion of multiple records of the same pregnancy registered in connection with hospital visits due to an earlier termination, a woman with the same diagnostic or procedure code for pregnancy termination was allowed to re-enter the cohort after 180 days, whereupon this was considered a different pregnancy. The same approach using diagnostic codes only was applied to define miscarriages. When multiple dates were available for each pregnancy termination or miscarriage episode, we included the earliest and it served as the index date. Our approach could potentially miss recurrent miscarriages within 180 days of each other. Finally, we excluded the pregnancies of women with the history of any cancer or HIV/AIDs diagnosis (Table S1 in the Supplemental materials).

Cancer outcomes

Using the DCR, we ascertained incident diagnoses of cancer. We investigated the long-term risk of any cancer; haematological, immune-related, alcohol and smoking-related, obesity-related cancers[35,36] and cancers at multiple specific sites, focusing specifically on breast, cervical, ovarian and fallopian tube, and uterine cancer (Table S1 in the Supplemental materials).

Covariables

The potential confounding factors were age, calendar year of pregnancy end, women's parity, socioeconomic factors (education, employment, and year-specific income level divided into quartiles), reproductive history (previous episodes of VB, at least one pregnancy termination or

miscarriage), and chronic somatic and psychiatric conditions (Figure S1 in the Supplemental materials). We additionally ascertained and adjusted for women's medication use before the index date as a measure of underlying health and healthcare utilization.

Statistical analyses

We followed women from the index date until the earliest of cancer diagnosis, death, emigration, or end of the study on 31 December 2017. Women with multiple cancers diagnosed at different dates were followed until the earliest of the diagnosed cancers. We computed the cumulative incidence of any cancer and haematological, immune-related, alcohol and smoking-related cancers at the end of 24-year follow-up while treating deaths and emigrations as competing events. We additionally reported the cumulative incidence of any cancer by women's age category. We computed crude incidence rates (IRs) per 10,000 person-years (PYs) of breast, cervical, ovarian and fallopian tube, uterine cancer and other cancers at specific sites as well as the incidence rate of any cancer by follow-up duration. We used Cox proportional hazards regression to compute crude and adjusted hazard ratios (HRs) for all investigated cancer outcomes. We computed 95% confidence intervals (CIs) using a robust standard error when different pregnancies of the same woman were analysed. In three separate sets of analyses, we compared the risk of cancer outcomes for VB-affected deliveries with that of VB-unaffected deliveries and pregnancies ending in a termination or miscarriage. For any cancer and haematological, immune-related, alcohol and smoking-related, and obesity-related cancers, we computed HRs adjusted for potential confounders (women's history of previous terminations, miscarriages, and VB episodes; history of thyroid conditions, obesity, chronic liver and kidney diseases, medication use as a proxy of women's overall health) using multivariable proportional hazards Cox regression. For these cancer outcomes, we additionally computed HRs using the average effect in the treated (ATT) weighting (the formula is available in the Supplemental materials). We performed truncation at the 1st and 99th percentile of the ATT weights distribution.[37,38] Further, we computed the risks of any cancer and cancers at specific sites

following women's first pregnancies. In a sensitivity analysis, we investigated the risk of any cancer and haematological, immune-related, alcohol and smoking-related, and obesity-related cancers additionally adjusted for women's BMI in pregnancy; however, the follow-up was short and accrued few events. We additionally investigated the risk of cancer restricting the data to women having their last recorded pregnancy at the age of 40 years or later.

Using log-minus-log plots, we visually evaluated the proportionality of hazards assumptions for all Cox proportional hazards analyses and the curves were close to parallel over the entire follow-up period. All analyses were conducted at Statistics Denmark[29] using RStudio[39] and R[40] versions 3.6.0-4.1.0 including the following packages and their dependencies: tidyverse,[41] ggplot2,[42] survival,[43] cmprsk,[44] prodlim,[45] epiR[46]. Reported counts were clouded whenever appropriate to protect personal data.

Ethics

No patient consent or ethical approval is required for registry-based research according to Danish legislation. This study was reported to the Danish Data Protection Agency[47] through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 605).

RESULTS

Descriptive characteristics

This study included 37,085 VB-affected deliveries among 35,517 women; 1,362,760 VB-unaffected deliveries among 783,020 women; 324,395 terminations among 239,729 women and 137,040 miscarriages among 121,303 women in 1995-2017 (Figure 1). Women's age, parity, civil status, employment, income, obesity, chronic pulmonary, liver and kidney conditions, alcohol abuse, and medication use had similar distributions for VB-affected and VB-unaffected deliveries. Of women with VB-affected vs VB-unaffected deliveries, 29.0% vs 35.0% had higher education, 13.0% vs 4.9% had a previous record of VB diagnosis irrespective of pregnancy outcome, 6.2% vs 2.1% had a history

of a previous VB episode within 20 gestational weeks of a pregnancy ending in a delivery, 22.0% vs 12.0% had at least one previous miscarriage; 19.0% vs 15.0% were smokers (Table 1).

Pregnancies ending in a termination were more likely to be of younger (<24 years), unmarried, nulliparous and unemployed women, who had a lower level of the highest attained education and were in the first income quartile compared with pregnancies ending in a delivery or miscarriage (Table 1). Pregnancies ending in a miscarriage were more likely than VB-affected deliveries to be of women older than 35 years and 15.0% had a previous miscarriage (Table 1).

Cumulative incidences and incidence rates of the cancer outcomes

During the follow-up of up to 24 years, there were 1,725 cancer events following VB-affected deliveries, 52,620 events following VB-unaffected deliveries, 12,925 events following a termination and 6,080 events following a miscarriage (Table 2). At the end of the follow-up, the cumulative incidence of any cancer was 9.9% for pregnancies ending in a delivery irrespective of whether or not they were complicated by VB. The cumulative incidence of any cancer following pregnancies ending in a termination or miscarriage was 9.3% (95% CI: 9.1%-9.6%) and 10.3% (95% CI: 9.9%-10.8%), respectively (Table 2). The highest cumulative incidence of any cancer was observed for women of 40+ years at pregnancy end (Figure S2 in the Supplemental materials). The cumulative incidence of haematological, immune-related, smoking and alcohol-related, and obesity-related cancers was similar for VB-affected and VB-unaffected deliveries as well as pregnancies ending in a termination or miscarriage (Table 2, Figure S3 in the Supplemental materials).

The incidence rate of any cancer was 32.1 (95% CI: 30.6-33.6) per 10,000 PYs for VB-affected deliveries and 31.5 (95% CI: 31.2-31.7) per 10,000 PYs for VB-affected deliveries (Table 2). The incidence rate of any cancer was slightly higher during the first 5 years of follow-up for every pregnancy cohort than during later follow-up periods (Table S2 in the Supplemental materials). The incidence rates of smoking and alcohol-related cancers and obesity-related cancers were slightly higher for VB-affected (1.6, 95% CI: 1.3-2.0 and 11.3, 95% CI: 11.4-11.7 per 10,000 PYs, respectively) vs VB-unaffected deliveries (1.5, 95% CI: 1.4-1.6 and 11.1, 95% CI: 10.9-11.3 per 10,000 PYs,

respectively) (Table 2). The incidence rates of breast, cervical, ovary and fallopian tube, uterine cancer, and cancers at other sites were similar for all ascertained cohorts of pregnancies (Table 2, Table S3 in the Supplemental materials).

Hazard ratios for the cancer outcomes

In the ATT-weighting adjusted analysis, the HR for any cancer among vaginal-bleeding affected deliveries was 0.98 (95% CI: 0.93-1.03) compared with VB-unaffected, 1.00 (95% CI: 0.94-1.06) compared with terminations, and 1.04 (95% CI: 0.94-1.14) compared with miscarriages. The conventionally adjusted models yielded nearly identical results, which remained unchanged in the subcohort of first pregnancies (Table 3).

There was no association between VB-affected pregnancy and subsequent risk of haematological, immune-related, obesity-related or other cancers across all comparators (Table 4, Table S4 in the Supplemental materials). When contrasting the risk of smoking and alcohol-related cancers following all VB-affected vs all VB-unaffected deliveries the HR was 0.92 (95% CI: 0.74-1.14). We observed a 38% increased hazard of smoking and alcohol-related cancers following first-recorded pregnancies (HR=1.38, 95% CI: 0.93-2.04), although the confidence interval was wide (Table 4, Table S4 in the Supplemental materials). There was a protective association for VB-affected deliveries with smoking and alcohol-related cancers when compared with pregnancies ending in a termination (HR=0.77, 95% CI: 0.60-0.98) or miscarriage (HR=0.64, 95% CI: 0.47-0.88). However, the latter associations could not be adjusted for women's smoking status and BMI, since this information was only available for pregnancies ending in a delivery.

As compared with VB-unaffected deliveries, there was no increase in relative risk of breast (HR=0.94, 95% CI: 0.86-1.03), cervical (0.94, 0.77-1.14), ovarian and fallopian tube (1.16, 0.81-1.66), and uterine cancer (0.78, 0.46-1.33) following VB-unaffected deliveries (Table 5). Similarly, we found no association with other investigated site-specific cancers across comparisons with VB-unaffected deliveries and pregnancies ending in a termination or miscarriage (Table S5 in the Supplemental materials).

Sensitivity analysis of pregnancies ending in delivery from 2004 onwards with additional adjustment for woman's BMI in pregnancy showed results consistent with the findings from the main analyses, however, some HRs for cancers at specific sites were inestimable due to short follow-up and few events (Table S6 in the Supplemental materials).

DISCUSSION

Principal findings

In this registry-based cohort study, we found no evidence of an association between VB in pregnancy carried to delivery and subsequent risk of cancer over the 24-year follow-up. When compared with VB-unaffected deliveries, there was no increased risk of any cancer and specifically breast, cervical, ovarian and fallopian tube, and uterine cancer in women. Similarly, we found no associations with any cancer and site-specific cancers in women when contrasting VB-affected deliveries with pregnancies ending in a termination or miscarriage.

Comparison with other studies

No other studies investigated an association of VB within 20 gestational weeks of pregnancy ending in delivery and subsequent risk of any cancer and cancers at multiple specific sites as compared with VB-unaffected deliveries and pregnancies ending in a termination or miscarriage. This study indirectly supports the findings of previous research on risk of breast, ovarian and endometrial cancer. These studies found that the risk was similarly reduced in women with gestation irrespective of whether the pregnancies were carried until delivery or not.[1,3,4] This study is also in line with a Danish study reporting no association between VB in pregnancy and occult cancer[21].

Strengths and limitations of the study

Due to nearly complete administrative follow-up for every woman, selection bias at inclusion of pregnancies in the cohorts is negligible, but potential selection bias from unidentified early miscarriages cannot be ruled out. In the analyses, we controlled for multiple potential confounding factors. Data on proxies of the lifestyle such as smoking and BMI were available only for pregnancies

ending in deliveries starting from 2004 and unavailable for pregnancies ending in miscarriages or terminations. At the same time, we have no reason to assume that in the context of Denmark, VB-affected and VB-unaffected deliveries would be of women with very different lifestyles. Moreover, no lifestyle factor of women with VB in pregnancy is likely to dilute the associations.

Diagnoses of VB in pregnancy due to threatened miscarriage was not validated in the DNPR. The validity of similar diagnoses for miscarriage and of diagnoses and procedures for pregnancy termination in the DNPR is high (positive predictive value >90%).[30,48] We could potentially miss recurrent miscarriages within 180 days of each other. However, owing to high specificity of miscarriage diagnoses and few false-positives, the misclassification of miscarriages is not a major concern. A diagnostic work-up for threatened miscarriage includes an ultrasound for establishing pregnancy viability, foetal heartbeat, and to eliminate other causes of VB such as ectopic pregnancy.[10,49] The prevalence of VB in this study is low (<3%) compared with estimates reported elsewhere (up to 30%)[10–14]. We argue that identified VB diagnoses in this study had high specificity, however, a large proportion of VB may be missed. This may cause bias only if captured episodes of VB systematically differ from all such episodes.

Owing to compulsory reporting of incident primary tumours, the accuracy of cancer diagnoses in the DCR and its coverage is very high, with nearly 90% of tumours having a morphological verification.[34] Thus, misclassification of the outcome is unlikely in this study and cannot explain the null findings.

CONCLUSION

We found no evidence of an association between VB in pregnancy and subsequent long-term risk of cancer.

Contributors: ED, EHP, HTS, VE designed the study. HTS facilitated the data application. ED prepared the statistical analysis plan and conducted statistical analyses. EHP provided expertise and supervision of the statistical analyses. All authors participated in the discussion of the results and their interpretation. ED drafted the manuscript, organised the writing, and produced a graphical presentation of the results. HTS provided clinical expertise. All authors equally participated in the critical revision of the manuscript and approved its final version. HTS is the guarantor.

Funding: Department of Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from regulators and pharmaceutical companies, given as research grants to and administered by Aarhus University. None of these projects is related to the current study.

Competing interests: All authors report no competing interest.

Ethics approval: Not required for registry-based research in Denmark.

Data sharing: Data is not available for sharing to protect the identity of participants according to Danish legislation.

Patient and public involvement: Patients or the public were not involved in the design, or conduct, or reporting, or dissemination of this research.

References:

1 Jordan SJ, Na R, Weiderpass E, *et al.* Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. *International Journal of Cancer* 2021;**148**:2068–78. doi:10.1002/ijc.33360

2 Ma H, Bernstein L, Pike MC, *et al.* Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast cancer research : BCR* 2006;**8**:R43. doi:10.1186/bcr1525

3 Husby A, Wohlfahrt J, Øyen N, *et al.* Pregnancy duration and breast cancer risk. *Nat Commun* 2018;**9**:4255. doi:10.1038/s41467-018-06748-3

4 Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide cohort study. *BMJ* 2019;**366**:l4693. doi:10.1136/bmj.l4693

5 Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. *Placenta* 2014;**35**:241–8. doi:10.1016/j.placenta.2014.02.004

6 Calleja-Agius J, Schembri-Wismayer P, Calleja N, *et al.* Obstetric outcome and cytokine levels in threatened miscarriage. *Gynecol Endocrinol* 2011;**27**:121–7. doi:10.3109/09513590.2010.487614

7 Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, *et al.* Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. *Clin Rev Allergy Immunol* 2017;**53**:40–53. doi:10.1007/s12016-016-8596-x

8 Coomarasamy A, Gallos ID, Papadopoulou A, *et al.* Sporadic miscarriage: evidence to provide effective care. *The Lancet* 2021;**397**:1668–74. doi:10.1016/S0140-6736(21)00683-8

9 Lek SM, Ku CW, Allen JC, *et al.* Validation of serum progesterone <35nmol/L as a predictor of miscarriage among women with threatened miscarriage. *BMC Pregnancy Childbirth* 2017;**17**:78. doi:10.1186/s12884-017-1261-4

10 Axelsen SM, Henriksen TB, Hedegaard M, *et al.* Characteristics of vaginal bleeding during pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1995;**63**:131–4. doi:10.1016/0301-2115(95)02236-8

11 Smits LJM, North RA, Kenny LC, *et al.* Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. *Acta Obstetricia et Gynecologica Scandinavica* 2012;**91**:1331–8. doi:10.1111/j.1600-0412.2012.01496.x

12 Strobino B, Pantel-Silverman J. Gestational vaginal bleeding and pregnancy outcome. *American Journal of Epidemiology* 1989;**129**:806–15. doi:10.1093/oxfordjournals.aje.a115195

13 Wijesiriwardana A, Bhattacharya S, Shetty A, *et al.* Obstetric Outcome in Women With Threatened Miscarriage in the First Trimester. *Obstetrics & Gynecology* 2006;**107**:557–62. doi:10.1097/01.AOG.0000199952.82151.de

14 Saraswat L, Bhattacharya S, Maheshwari A, *et al.* Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. *BJOG* 2010;**117**:245–57. doi:10.1111/j.1471-0528.2009.02427.x

15 DeVilbiss EA, Naimi AI, Mumford SL, *et al.* Vaginal bleeding and nausea in early pregnancy as predictors of clinical pregnancy loss. *American Journal of Obstetrics and Gynecology* 2020;**223**:570.e1-570.e14. doi:10.1016/j.ajog.2020.04.002

16 Sapra KJ, Joseph KS, Galea S, *et al.* Signs and Symptoms of Early Pregnancy Loss. *Reprod Sci* 2017;**24**:502–13. doi:10.1177/1933719116654994

17 Mouri M, Hall H, Rupp TJ. *Threatened Abortion*. 2017. http://europepmc.org/article/NBK/NBK430747 (accessed 6 Apr 2021).

18 Coomarasamy A, Devall AJ, Cheed V, *et al.* A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. *New England Journal of Medicine* 2019;**380**:1815–24. doi:10.1056/NEJMoa1813730

19 Ogwulu CO, Goranitis I, Devall AJ, *et al.* The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. *BJOG: An International Journal of Obstetrics & Gynaecology* 2020;**127**:757–67. doi:https://doi.org/10.1111/1471-0528.16068

20 Quenby S, Gallos ID, Dhillon-Smith RK, *et al.* Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. *The Lancet* 2021;**397**:1658–67. doi:10.1016/S0140-6736(21)00682-6

21 Dudukina E, Farkas DK, Horváth-Puhó E, *et al.* Vaginal bleeding in early pregnancy and risk of occult cancer. *International Journal of Gynecology & Obstetrics* 2019;**146**:387–9. doi:10.1002/ijgo.12867

22 Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol* 2014;**29**:541–9. doi:10.1007/s10654-014-9930-3

23 Pedersen CB. The Danish Civil Registration System. *Scandinavian Journal of Public Health* 2011;**39**:22–5. doi:10.1177/1403494810387965

24 Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Danish medical bulletin* 1998;**45**:320–3.

25 Bliddal M, Broe A, Pottegard A, *et al.* The Danish Medical Birth Register. *Eur J Epidemiol* 2018;**33**:27–36. doi:10.1007/s10654-018-0356-1

26 Jensen VM, Rasmussen AW. Danish Education Registers. *Scand J Public Health* 2011;**39**:91–4. doi:10.1177/1403494810394715

27 Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health* 2011;**39**:95–8. doi:10.1177/1403494811408483

28 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public Health* 2011;**39**:103–5. doi:10.1177/1403494811405098

29 Statistics Denmark. 2021.https://www.dst.dk/en (accessed 30 Jun 2021).

30 Schmidt M, Schmidt SA, Sandegaard JL, *et al.* The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;**7**:449–90. doi:10.2147/CLEP.S91125

31 Laugesen K, Ludvigsson JF, Schmidt M, *et al.* Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. *CLEP* 2021;**13**:533–54. doi:10.2147/CLEP.S314959

32 Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. *Scand J Public Health* 2011;**39**:54–7. doi:10.1177/1403494810395825

33 Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, *et al.* Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol* 2017;**46**:798–798f. doi:10.1093/ije/dyw213

34 Gjerstorff ML. The Danish Cancer Registry. *Scand J Public Health* 2011;**39**:42–5. doi:10.1177/1403494810393562

35 Ording AG, Veres K, Farkas DK, *et al.* Risk of cancer in patients with epistaxis and haemoptysis. *Br J Cancer* 2018;**118**:913–9. doi:10.1038/bjc.2017.494

36 Gribsholt SB, Cronin-Fenton D, Veres K, *et al.* Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. *Journal of Internal Medicine* 2020;**287**:435–47. doi:10.1111/joim.13013

37 Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol* 2008;**168**:656–64. doi:10.1093/aje/kwn164

38 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med* 2015;**34**:3661–79. doi:10.1002/sim.6607

39 RStudio Team. *RStudio: Integrated Development for R*. Boston, MA: : RStudio, PBC 2020. http://www.rstudio.com/

40 R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: 2013. http://www.R-project.org/

41 Wickham H, Averick M, Bryan J, *et al.* Welcome to the Tidyverse. *Journal of Open Source Software* 2019;**4**:1686. doi:10.21105/joss.01686

42 Wickham H. *ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis*. Springer-Verlag New York 2016. https://ggplot2.tidyverse.org

43 Therneau TM, Thomas L, Elizabeth A, *et al. survival: Survival Analysis*. 2021. https://CRAN.R-project.org/package=survival (accessed 6 Apr 2021).

44 Gray B. *cmprsk: Subdistribution Analysis of Competing Risks*. 2020. https://CRAN.R-project.org/package=cmprsk (accessed 31 Mar 2021).

45 Gerds TA. *prodlim: Product-Limit Estimation for Censored Event History Analysis*. 2019. https://CRAN.R-project.org/package=prodlim (accessed 31 Mar 2021).

46 Nunes MS and ES with contributions from T, Heuer C, Marshall J, *et al. epiR: Tools for the Analysis of Epidemiological Data*. 2021. https://CRAN.R-project.org/package=epiR (accessed 29 Jul 2021).

47 Datatilsynet. Datatilsynet/The Danish Data Protection Agency. Datatilsynet/The Danish Data Protection Agency. http://www.datatilsynet.dk/english (accessed 16 Sep 2020).

48 Lohse SR, Farkas DK, Lohse N, *et al.* Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. *Clin Epidemiol* 2010;**2**:247–50. doi:10.2147/CLEP.S13815

49 Norwitz ER, Park JS, Lockwood CJ, *et al.* Overview of the etiology and evaluation of vaginal bleeding in pregnancy - UpToDate. 2021.https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-bleeding-in-pregnancy (accessed 30 Aug 2021).

Figure 1. Flow chart for the pregnancy cohorts' ascertainment

Table 1. Descriptive characteristics of vaginal bleeding-affected deliveries, vaginal bleeding-unaffected deliveries, pregnancies ending in a termination or miscarriage, Denmark, 1995-2017

Characteristic	VB-affected deliveries, N = 37,085 (35,517 women)		VB-unaffected deliveries, N = 1,362,760 (783,020 women)		Terminations, N = 324,395 (239,729 women)		Miscarriages, N = 137,040 (121,303 women)	
	N	%	N	%	N	%	N	%
Age at pregnancy, years								
<20	565	1.5	20,015	1.5	46,220	14.0	4,635	3.4
20-24	5,035	14.0	163,915	12.0	74,415	23.0	17,415	13.0
25-29	12,270	33.0	464,200	34.0	68,090	21.0	37,455	27.0
30-34	12,375	33.0	476,165	35.0	65,405	20.0	39,795	29.0
35-39	5,715	15.0	202,300	15.0	49,440	15.0	26,135	19.0
40+	1,125	3.0	36,165	2.7	20,655	6.4	11,535	8.4
missing[a]	0	0.0	0	0.0	170	0.1	70	0.1
Calendar year of pregnancy								
1995-1999	12,660	34.0	308,280	23.0	88,975	27.0	33,555	24.0
2000-2004	8,265	22.0	243,000	18.0	63,425	20.0	25,460	19.0
2005-2008	7,220	19.0	304,200	22.0	72,315	22.0	33,855	25.0
2009-2013	4,730	13.0	228,775	17.0	50,595	16.0	25,345	18.0
2013-2017	4,205	11.0	278,500	20.0	49,080	15.0	18,820	14.0
Smoking in pregnancy								
Smoker	6,995	19.0	209,830	15.0	N/A	N/A	N/A	N/A
Non-smoker	26,205	71.0	1,048,830	77.0	N/A	N/A	N/A	N/A
Missing	3,885	10.0	104,095	7.6	N/A	N/A	N/A	N/A
Parity at the index or at the delivery date								
Nulliparous	0	0.0	0	0.0	205,465	63.0	110,445	81.0
Primiparous	17,105	46.0	628,845	46.0	32,750	10.0	10,870	7.9
Multiparous	19,980	54.0	733,910	54.0	86,180	27.0	15,725	11.0
Pregnancy number at the index date								
1	11,795	32.0	512,325	38.0	112,430	35.0	43,950	32.0
2	11,140	30.0	447,200	33.0	59,720	18.0	39,880	29.0
3+	14,150	38.0	403,230	30.0	152,245	47.0	53,210	39.0
BMI category, kg/m^2, 2004-2017								
< 18.49	905	2.4	35,280	2.6	N/A	N/A	N/A	N/A
18.5-24.99	10,080	27.0	484,830	36.0	N/A	N/A	N/A	N/A
25.0-29.99	3,285	8.9	165,200	12.0	N/A	N/A	N/A	N/A
30.0+	2,220	6.0	97,555	7.2	N/A	N/A	N/A	N/A
missing	20,590	56.0	579,895	43.0	N/A	N/A	N/A	N/A
Civil status								
Married or in partnership	21,980	59.0	819,015	60.0	103,120	32.0	67,870	50.0
Not married	10,380	28.0	383,100	28.0	163,720	50.0	42,675	31.0
Missing	4,720	13.0	160,640	12.0	57,550	18.0	26,495	19.0
Employment status								
Employed	26,965	73.0	1,017,100	75.0	194,750	60.0	98,565	72.0

Characteristic	VB-affected deliveries, N = 37,085 (35,517 women)		VB-unaffected deliveries, N = 1,362,760 (783,020 women)		Terminations, N = 324,395 (239,729 women)		Miscarriages, N = 137,040 (121,303 women)	
	N	%	N	%	N	%	N	%
Retirement or state pension	3,400	9.2	100,585	7.4	41,220	13.0	13,025	9.5
Unemployed	5,750	15.0	201,390	15.0	80,915	25.0	21,325	16.0
Missing	970	2.6	43,685	3.2	7,510	2.3	4,125	3.0
Highest achieved education								
Basic education	9,825	26.0	272,035	20.0	145,845	45.0	35,665	26.0
High school or similar	15,095	41.0	553,225	41.0	109,285	34.0	53,350	39.0
Higher education	10,595	29.0	472,920	35.0	48,885	15.0	41,065	30.0
Missing	1,565	4.2	64,575	4.7	20,375	6.3	6,955	5.1
Year-specific income, quartiles								
Q1	8,905	24.0	282,170	21.0	130,565	40.0	33,140	24.0
Q2	9,460	26.0	326,525	24.0	82,275	25.0	34,485	25.0
Q3	8,880	24.0	358,770	26.0	52,535	16.0	32,670	24.0
Q4	9,170	25.0	361,665	27.0	47,110	15.0	33,130	24.0
missing	675	1.8	33,625	2.5	11,905	3.7	3,620	2.6
Reproductive history								
Previous VB diagnosis	4,865	13.0	66,285	4.9	23,920	7.4	16,995	12.0
Previous VB within 20 gestational weeks of a pregnancy ending in a delivery	2,315	6.2	29,275	2.1	11,990	3.7	5,040	3.7
Previous pregnancy termination	8,615	23.0	224,265	16.0	110,440	34.0	30,170	22.0
Previous miscarriage	8,095	22.0	165,495	12.0	38,620	12.0	20,915	15.0
Comorbidities								
Obesity diagnosis	1,590	4.3	128,030	9.4	13,350	4.1	6,775	4.9
Thyroid disorders	780	2.1	30,895	2.3	5,100	1.6	2,985	2.2
COPD	450	1.2	14,140	1.0	3,410	1.1	1,450	1.1
Chronic kidney disease	105	0.3	2,775	0.2	775	0.2	305	0.2
Chronic liver disease	85	0.2	3,400	0.2	955	0.3	385	0.3
Hyperlipidaemia	10	0.1	375	0.1	85	0.1	50	0.1
Hypercholesterolemia	40	0.1	1,485	0.1	355	0.1	190	0.1
Diabetes type 1 and 2	200	0.5	7,845	0.6	1,770	0.5	1,025	0.7
Hypertension	205	0.6	7,725	0.6	1,705	0.5	960	0.7
Ischaemic heart disease	55	0.1	1,440	0.1	585	0.2	275	0.2
Heart failure	20	0.1	370	0.1	115	0.1	70	0.1
Ischaemic stroke	55	0.1	1,255	0.1	450	0.1	195	0.1
Haemorrhagic stroke	50	0.1	1,195	0.1	395	0.1	175	0.1
Deep vein thrombosis	115	0.3	4,525	0.3	1,220	0.4	565	0.4
Pulmonary embolism	65	0.2	1,910	0.1	510	0.2	245	0.2
Psychiatric comorbidities								
Schizophrenia	325	0.9	8,685	0.6	5,735	1.8	1,345	1.0
Autism spectrum disorders	30	0.1	845	0.1	545	0.2	105	0.1

Characteristic	VB-affected deliveries, N = 37,085 (35,517 women)		VB-unaffected deliveries, N = 1,362,760 (783,020 women)		Terminations, N = 324,395 (239,729 women)		Miscarriages, N = 137,040 (121,303 women)	
	N	**%**	**N**	**%**	**N**	**%**	**N**	**%**
Neurotic disorders	3,565	9.6	92,270	6.8	42,875	13.0	12,035	8.8
Eating disorders	475	1.3	14,095	1.0	5,705	1.8	1,650	1.2
Personality disorder	1,295	3.5	31,330	2.3	19,185	5.9	4,740	3.5
Alcohol abuse history	365	1.0	9,680	0.7	10,315	3.2	1,990	1.5
History of any psychiatric condition	5,005	13.0	140,570	10.0	61,990	19.0	17,730	13.0
Medication use								
At least one prescription any time before the index date								
Antipsychotics	995	2.7	28,560	2.1	14,225	4.4	4,355	3.2
Mood disorders medication	4,370	12.0	140,965	10.0	50,355	16.0	18,050	13.0
Antiepileptics	765	2.1	24,320	1.8	8,540	2.6	3,185	2.3
ADHD medication	135	0.4	4,825	0.4	3,375	1.0	645	0.5
NSAIDs	18,830	51.0	664,725	49.0	153,020	47.0	71,930	52.0
Aspirin	180	0.5	6,475	0.5	1,260	0.4	730	0.5
Thyroid disorders medication	670	1.8	25,295	1.9	4,410	1.4	2,745	2.0
Steroids for systemic use	2,850	7.7	103,830	7.6	20,780	6.4	11,375	8.3
Anti-infectives for systemic use	32,055	86.0	1,180,555	87.0	281,690	87.0	119,110	87.0
Within 30 days before the index date								
Anti-infectives for systemic use	2,950	8.0	81,605	6.0	33,290	10.0	10,160	7.4
Antiepileptics	110	0.3	3,525	0.3	1,560	0.5	470	0.3
Antidepressants	280	0.8	7,575	0.6	7,360	2.3	1,730	1.3
CVD medication[b]	380	1.0	43,980	3.2	3,155	1.0	1,805	1.3
NSAIDs	230	0.6	1,950	0.1	5,995	1.8	1,790	1.3

[a] Observations with missing women's age were excluded from the analyses

[b] CVD medications included clopidogrel, statins, any of antihypertensives

Table 2. Cumulative incidences and incidence rates of any cancer, haematological, immune-related, smoking and alcohol-related, and obesity-related cancers following vaginal bleeding-affected deliveries, vaginal bleeding-unaffected deliveries, and pregnancies ending in a termination or miscarriage, 1995-2017

	VB-affected deliveries, N = 37,085 (35,517 women)	VB-unaffected deliveries, N = 1,362,760 (783,020 women)	Terminations, N = 324,395 (239,729 women)	Miscarriages, N = 137,040 (121,303 women)
	N, events[a]			
Any cancer				
All pregnancies	1,725	52,620	12,925	6,080
First pregnancies	455	16,340	2,720	1,380
Haematological cancers				
All pregnancies	50	1,675	455	235
First pregnancies	15	545	95	50
Immune-related cancers				
All pregnancies	870	26,935	6,320	2,840
First pregnancies	225	8,760	1,495	695
Smoking and alcohol-related cancers				
All pregnancies	90	2,490	935	370
First pregnancies	25	600	120	60
Obesity-related cancers				
All pregnancies	605	18,565	4,360	2,280
First pregnancies	160	5,500	825	490
Other cancers				
All pregnancies	110	2,960	855	360
First pregnancies	30	930	185	85
Selected site-specific cancers				
All pregnancies				
Breast cancer	475	14,540	3,340	1,795
Cervical cancer	105	3,430	955	315
Ovary and fallopian tube cancer	30	760	215	110
Uterine cancer	15	495	105	65
	Cumulative incidences, %			
Any cancer				
All pregnancies	9.9 (9.2-10.6)	9.9 (9.8-10.1)	9.3 (9.1-9.6)	10.3 (9.9-10.8)
First pregnancies	9.1 (7.9-10.4)	8.7 (8.5-9.0)	6.4 (6.0-6.9)	8.1 (7.5-8.7)
Haematological cancers				
All pregnancies	0.3 (0.2-0.5)	0.3 (0.3-0.3)	0.3 (0.3-0.4)	0.4 (0.3-0.5)
First pregnancies	0.2 (0.1-0.5)	0.3 (0.2-0.3)	0.2 (0.1-0.2)	0.2 (0.2-0.4)
Immune-related cancers				
All pregnancies	4.7 (4.3-5.2)	4.8 (4.7-4.9)	4.2 (4.1-4.4)	4.6 (4.3-4.9)
First pregnancies	4.3 (3.6-5.2)	4.5 (4.3-4.6)	3.2 (2.9-3.4)	3.9 (3.5-4.3)
Smoking and alcohol-related cancers				
All pregnancies	0.6 (0.4-0.7)	0.6 (0.6-0.7)	0.9 (0.8-1.1)	0.8 (0.7-0.9)

	VB-affected deliveries, N = 37,085 (35,517 women)	VB-unaffected deliveries, N = 1,362,760 (783,020 women)	Terminations, N = 324,395 (239,729 women)	Miscarriages, N = 137,040 (121,303 women)
First pregnancies	0.6 (0.4-1.1)	0.4 (0.4-0.5)	0.5 (0.3-0.7)	0.4 (0.3-0.6)
Obesity-related cancers				
All pregnancies	3.7 (3.3-4.2)	3.6 (3.5-3.7)	3.2 (3.1-3.4)	4.0 (3.7-4.3)
First pregnancies	3.4 (2.6-4.4)	3.1 (3.0-3.3)	2.2 (1.9-2.5)	3.1 (2.7-3.6)
Other cancers				
All pregnancies	0.6 (0.5-0.8)	0.5 (0.5-0.6)	0.6 (0.5-0.7)	0.6 (0.5-0.7)
First pregnancies	0.5 (0.3-0.8)	0.5 (0.4-0.6)	0.4 (0.3-0.5)	0.4 (0.3-0.5)
	Incidence Rate, 10 000 PYs (95% CI)			
Any cancer				
All pregnancies	32.10 (30.61-33.64)	31.45 (31.18-31.72)	30.10 (29.58-30.62)	34.27 (33.42-35.14)
First pregnancies	28.71 (26.17-31.44)	27.25 (26.83-27.67)	19.11 (18.40-19.83)	26.80 (25.41-28.24)
Haematological cancers				
All pregnancies	0.95 (0.71-1.24)	1.00 (0.96-1.05)	1.06 (0.97-1.16)	1.31 (1.15-1.49)
First pregnancies	0.82 (0.46-1.36)	0.91 (0.83-0.99)	0.68 (0.56-0.83)	0.93 (0.70-1.23)
Immune-related cancers				
All pregnancies	16.20 (15.15-17.30)	16.10 (15.90-16.29)	14.72 (14.36-15.08)	16.00 (15.42-16.60)
First pregnancies	14.20 (12.44-16.14)	14.61 (14.31-14.92)	10.50 (9.98-11.04)	13.47 (12.49-14.50)
Smoking and alcohol-related cancers				
All pregnancies	1.64 (1.32-2.01)	1.49 (1.43-1.55)	2.18 (2.05-2.32)	2.07 (1.87-2.30)
First pregnancies	1.63 (1.09-2.36)	1.00 (0.92-1.08)	0.84 (0.70-1.00)	1.20 (0.93-1.53)
Obesity-related cancers				
All pregnancies	11.25 (10.38-12.17)	11.09 (10.93-11.25)	10.15 (9.85-10.45)	12.84 (12.32-13.38)
First pregnancies	10.05 (8.58-11.70)	9.18 (8.94-9.42)	5.80 (5.41-6.20)	9.50 (8.69-10.37)
Other cancers				
All pregnancies	2.06 (1.71-2.48)	1.77 (1.71-1.83)	1.99 (1.86-2.12)	2.04 (1.83-2.25)
First pregnancies	2.01 (1.40-2.80)	1.55 (1.45-1.65)	1.28 (1.11-1.48)	1.69 (1.36-2.07)
Selected site-specific cancers				
All pregnancies				
Breast cancer	8.85 (8.08-9.67)	8.70 (8.56-8.84)	7.80 (7.54-8.07)	10.14 (9.67-10.61)
Cervical cancer	1.94 (1.59-2.34)	2.05 (1.99-2.12)	2.23 (2.09-2.37)	1.79 (1.60-2.00)
Ovary and fallopian tube cancer	0.60 (0.42-0.83)	0.45 (0.42-0.49)	0.50 (0.44-0.57)	0.62 (0.51-0.75)
Uterine cancer	0.26 (0.15-0.43)	0.30 (0.27-0.32)	0.25 (0.20-0.30)	0.37 (0.29-0.47)

Table 3. Hazard ratios (HRs) with 95% confidence intervals (CIs) for any cancer, 1995-2017

	Model	HR (95% CI)
VB-affected deliveries vs VB-unaffected deliveries[a]		
All pregnancy records	Crude	0.96 (0.91-1.01)
	Conventionally adjusted[b]	0.97 (0.92-1.01)
	ATT-weighted[c]	0.98 (0.93-1.03)
First pregnancy records	Crude	0.99 (0.91-1.09)
	Conventionally adjusted[b]	0.97 (0.88-1.06)
	ATT-weighted[c]	0.98 (0.90-1.08)
VB-affected deliveries vs terminations[d]		
All pregnancy records	Crude	1.02 (0.97-1.08)
	Conventionally adjusted[b]	0.88 (0.77-1.00)
	ATT-weighted[c]	1.00 (0.94-1.06)
First pregnancy records	Crude	1.45 (1.31-1.60)
	Conventionally adjusted[b]	0.88 (0.68-1.13)
	ATT-weighted[c]	0.95 (0.83-1.08)
VB-affected deliveries vs miscarriages[d]		
All pregnancy records	Crude	0.89 (0.84-0.93)
	Conventionally adjusted[b]	0.90 (0.79-1.02)
	ATT-weighted[c]	1.04 (0.94-1.14)
First pregnancy records	Crude	1.01 (0.91-1.13)
	Conventionally adjusted[b]	1.02 (0.80-1.32)
	ATT-weighted[c]	1.16 (1.02-1.32)

[a] Adjusted for age, calendar year of pregnancy end, women's parity, smoking socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), reproductive history (previous episodes of vaginal bleeding, pregnancy terminations and miscarriages), chronic somatic and psychiatric conditions, and women's medication use before the index date available from 1995 (as a proxy for overall underlying health and healthcare-seeking behaviour).

[b] Models were adjusted using multivariable Cox proportional hazards regression.

[c] ATT-weighted and conventionally adjusted models included the same adjustment set of covariables.

[d] Analyses could not be adjusted for smoking or body mass index since the data on these covariables are unavailable for pregnancies ending in a termination or miscarriage.

Table 4. Hazard ratios (HRs) with 95% confidence intervals (CIs) for haematological, immune-related, smoking and alcohol-related, and obesity-related cancers, 1995-2017

Outcome		HR (95% CI)
VB-affected deliveries vs VB-unaffected deliveries[a]		
Haematological cancers	All pregnancies	0.91 (0.69-1.20)
	First pregnancies	0.85 (0.49-1.48)
Immune-related cancers	All pregnancies	0.99 (0.93-1.06)
	First pregnancies	0.93 (0.81-1.06)
Smoking and alcohol-related cancers	All pregnancies	0.92 (0.74-1.14)
	First pregnancies	1.38 (0.93-2.04)
Obesity-related cancers	All pregnancies	0.96 (0.88-1.04)
	First pregnancies	1.00 (0.85-1.17)
Other cancers	All pregnancies	1.08 (0.89-1.31)
	First pregnancies	1.22 (0.86-1.74)
VB-affected deliveries vs terminations[b]		
Haematological cancers	All pregnancies	0.83 (0.60-1.16)
	First pregnancies	0.71 (0.36-1.38)
Immune-related cancers	All pregnancies	0.94 (0.87-1.02)
	First pregnancies	0.84 (0.72-0.99)
Smoking and alcohol-related cancers	All pregnancies	0.77 (0.60-0.98)
	First pregnancies	1.07 (0.66-1.75)
Obesity-related cancers	All pregnancies	0.92 (0.84-1.01)
	First pregnancies	0.92 (0.76-1.12)
Other cancers	All pregnancies	0.82 (0.66-1.03)
	First pregnancies	1.15 (0.73-1.80)
VB-affected deliveries vs miscarriages[b]		
Haematological cancers	All pregnancies	0.61 (0.38-0.97)
	First pregnancies	0.92 (0.49-1.73)
Immune-related cancers	All pregnancies	1.01 (0.90-1.13)
	First pregnancies	0.99 (0.85-1.16)
Smoking and alcohol-related cancers	All pregnancies	0.64 (0.47-0.88)
	First pregnancies	1.50 (0.93-2.41)
Obesity-related cancers	All pregnancies	0.90 (0.79-1.01)
	First pregnancies	1.01 (0.84-1.22)
Other cancers	All pregnancies	0.96 (0.71-1.29)
	First pregnancies	1.15 (0.75-1.77)

[a] Adjusted for age, calendar year of pregnancy end, women's parity, smoking, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), reproductive history (previous episodes of vaginal bleeding, pregnancy terminations and miscarriages), chronic somatic and psychiatric conditions, and women's medication use before the index date available from 1995 (as a proxy for overall underlying health and healthcare-seeking behaviour).

[b] Analyses could not be adjusted for smoking or body mass index since the data on these covariables are unavailable for pregnancies ending in a termination or miscarriage.

Table 5. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of breast cancer, cervical cancer, ovarian and fallopian tube cancer, and uterine cancer, 1995-2017

	Model	HR (95% CI)
VB-affected deliveries vs VB-unaffected deliveries[a]		
Breast cancer	Crude	0.95 (0.86-1.04)
	Conventionally adjusted[b]	0.94 (0.86-1.03)
Cervical cancer	Crude	0.94 (0.77-1.15)
	Conventionally adjusted[b]	0.94 (0.77-1.14)
Ovarian and fallopian tube cancer	Crude	1.21 (0.86-1.72)
	Conventionally adjusted[b]	1.16 (0.81-1.66)
Uterine cancer	Crude	0.78 (0.44-1.37)
	Conventionally adjusted[b]	0.78 (0.46-1.33)
VB-affected deliveries vs terminations[c]		
Breast cancer	Crude	1.08 (0.98-1.19)
	Conventionally adjusted[b]	0.98 (0.88-1.08)
Cervical cancer	Crude	0.86 (0.70-1.06)
	Conventionally adjusted[b]	0.80 (0.65-0.99)
Ovarian and fallopian tube cancer	Crude	1.12 (0.78-1.63)
	Conventionally adjusted[b]	0.92 (0.63-1.37)
Uterine cancer	Crude	0.98 (0.54-1.77)
	Conventionally adjusted[b]	0.97 (0.54-1.74)
VB-affected deliveries vs miscarriages[c]		
Breast cancer	Crude	0.82 (0.74-0.91)
	Conventionally adjusted[b]	0.95 (0.84-1.06)
Cervical cancer	Crude	1.08 (0.86-1.35)
	Conventionally adjusted[b]	0.98 (0.75-1.27)
Ovarian and fallopian tube cancer	Crude	0.90 (0.62-1.32)
	Conventionally adjusted[b]	0.88 (0.56-1.38)
Uterine cancer	Crude	0.63 (0.34-1.16)
	Conventionally adjusted[b]	0.65 (0.34-1.24)

[a] Adjusted for age, calendar year of pregnancy end, women's parity, smoking, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), reproductive history (previous episodes of vaginal bleeding, pregnancy terminations and miscarriages), chronic somatic and psychiatric conditions, and women's medication use before the index date available from 1995 (as a proxy for overall underlying health and healthcare-seeking behaviour)

[b] Analyses were adjusted using multivariable Cox proportional hazard regression

[c] Analyses could not be adjusted for smoking or body mass index since the data on these covariables are unavailable for pregnancies ending in a termination or miscarriage


1,490,389 records:
Still- and live births in Denmark, 1973-1996:
1,483,364 Live births
7,025 Stillbirths
1,338,638 records:
Still- and live births in Denmark, 1997-2017:
1,332,848 Live births
5,790 Stillbirths
2,829,027 records:
N, women = 1,443,429
Still- and live births in Denmark, 1973-2017:
Including 89,723 infants born from multi-fetal deliveries
2,816,212 Live births
12,815 Stillbirths
203,528 records:
Vaginal bleeding hospital diagnoses, the DNPR
(1977-2018); N, women = 120,697
414,405 records:
Hospital encounters for miscarriages, the DNPR;
N, women = 243,743
Excluded: Non-unique identifiers of the children (N=15)
One identifier randomly selected for each multi-fetal delivery is kept (N = 44,458)
2,783,747 records:
2,771,570 Live births
12,177 Stillbirths
92,806 records:
Vaginal bleeding hospital diagnoses within 20
gestational weeks; N, women = 67,555
287,426 records:
Distinct primary and secondary hospital diagnoses for miscarriages, the
DNPR N, women = 243,743
747,237 records:
Hospital diagnoses for pregnancy terminations, the
DNPR (1979-2018); N, women = 453,396
241,974 records:
Records of procedures for pregnancy terminations, the
DNPR; N, women = 183,804
Excluded records:
402,068 Records outside of the period 1979-2017
2,381,679 records:
Pregnancies ending in still- and live births, 1979-2017
N, women = 1,240,002
646,224 records:
Distinct records for pregnancy terminations, the DNPR
N, women = 465,813
3,408,135 Pregnancy records:
N, women = 1,411,869
Excluded 1,546,862 records:
14,511 Repeated episodes of vaginal bleeding in pregnancy
71,450 Unknown gestational age
6749 Encounters for different reproductive events (delivery, miscarriage, termination, vaginal bleeding) registered on the same date
67,923 Dates of encounters for reproductive events (delivery, miscarriage, termination, vaginal bleeding) after 2017
1,292,491 Pregnancies before 1995
70,897 Excluded from childbirths due to vaginal bleeding episode
13,752 History of cancer before the index date
957 History of AIDS before the index date
8,132 Personal identifier not found in the CRS or emigrated before the index date
Final study population (clouded counts)
1,861,275 pregnancies (1995-2017) of 887,759 distinct women
1,362,760 Pregnancies unaffected by vaginal bleeding and ending in childbirths (783,020 women)
37,085 Pregnancies affected by vaginal bleeding within 20 gestational weeks and ending in childbirths (35,517 women)
324,395 Pregnancies ending in a termination (239,729 women)
137,040 Pregnancies ending in a miscarriage (121,303 women)